Literature DB >> 4700503

Liver cell dysplasia: a premalignant condition.

P P Anthony, C L Vogel, L F Barker.   

Abstract

Liver cell dysplasia is defined as cellular enlargement, nuclear pleomorphism, and multinucleation of liver cells occurring in groups or occupying whole cirrhotic nodules. The prevalence, natural history, and relationship to the Australia or hepatitis-associated antigen (HAA) have been studied in 552 Ugandan African patients with normal, cirrhotic, and cancerous livers. Liver cell dysplasia was found in only two of 200 (1%) patients with normal livers, in three of 43 (6.9%) of patients with normal livers bearing primary liver cell carcinoma, 35 of 175 (20.3%) patients with cirrhosis, and 80 of 124 (64.5%) of patients with cirrhosis and primary liver cell carcinoma. Cirrhotic patients without dysplasia were, on average, ten years younger than those with dysplasia and the latter were on average six years younger than those with cirrhosis and carcinoma. Liver cell dysplasia occurred more frequently in males than in females. It was found in all but one instance in macronodular or mixed forms of cirrhosis only. There was a strong relationship between dysplasia and the presence of HAA in 104 patients that suggests a possible carcinogenic mechanism for the longincubation (serum or B) hepatitis virus in liver cell carcinoma. It is concluded that the presence of liver cell dysplasia identifies a group of patients with a high risk of liver cell carcinoma and that they should be followed up by serial alpha-fetoprotein estimations.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4700503      PMCID: PMC477688     

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

1.  Primary and metastatic carcinoma of the liver. Relationship to hepatic cirrhosis.

Authors:  E A GALL
Journal:  Arch Pathol       Date:  1960-08

2.  Cirrhosis and primary liver-cell carcinoma in Uganda.

Authors:  A G Shaper
Journal:  Trop Geogr Med       Date:  1970-06

3.  Virus-like antigen, antibody, and antigen-antibody complexes in hepatitis measured by complement fixation.

Authors:  N R Shulman; L F Barker
Journal:  Science       Date:  1969-07-18       Impact factor: 47.728

4.  Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma.

Authors:  C L Vogel; P P Anthony; N Mody; L F Barker
Journal:  Lancet       Date:  1970-09-26       Impact factor: 79.321

5.  Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data.

Authors:  G I Abelev
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

Review 6.  Role of serum hepatitis virus in chronic liver disease.

Authors:  A M Prince
Journal:  Gastroenterology       Date:  1971-05       Impact factor: 22.682

7.  Suppression of malignancy by cell fusion.

Authors:  H Harris; O J Miller; G Klein; P Worst; T Tachibana
Journal:  Nature       Date:  1969-07-26       Impact factor: 49.962

8.  Some aspects of liver disease in Ugandan Africans.

Authors:  M S Hutt
Journal:  Trans R Soc Trop Med Hyg       Date:  1971       Impact factor: 2.184

9.  Hepatitis-associated antigen and cirrhosis in Uganda.

Authors:  E P Maynard; F Sadikali; P P Anthony; L F Barker
Journal:  Lancet       Date:  1970-12-26       Impact factor: 79.321

10.  Rapid detection of Australia antigen by counterimmunoelectrophoresis.

Authors:  D J Gocke; C Howe
Journal:  J Immunol       Date:  1970-04       Impact factor: 5.422

View more
  40 in total

1.  Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis.

Authors:  C Chapoutot; M Esslimani; Z Joomaye; J Ramos; P Perney; C Laurent; P Fabbro-Peray; D Larrey; J Domergue; F Blanc
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

2.  Liver cell dysplasia and risk of hepatocellular carcinoma in cirrhosis: a preliminary report.

Authors:  M Borzio; S Bruno; M Roncalli; G C Mels; G Ramella; F Borzio; G Leandro; M Podda
Journal:  BMJ       Date:  1991-06-01

3.  Comparison of the proliferative capacity of adenomatous hyperplasia and well differentiated hepatocellular carcinoma.

Authors:  A Yamashita
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

4.  Liver aspiration in the diagnosis of hepatocellular carcinoma in the Gambia.

Authors:  A Ajdukiewicz; A Crowden; E Hudson; C Pyne
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

5.  Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridisation.

Authors:  A Marchio; B Terris; M Meddeb; P Pineau; A Duverger; P Tiollais; A Bernheim; A Dejean
Journal:  Mol Pathol       Date:  2001-08

Review 6.  The status of zinc in the development of hepatocellular cancer: an important, but neglected, clinically established relationship.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

7.  Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Scott J Cotler; Nissim Hay; Hui Xie; Mei Ling Chen; Pei Zhang Xu; Thomas J Layden; Grace Guzman
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

8.  Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis.

Authors:  M Borzio; D Trerè; F Borzio; A R Ferrari; S Bruno; M Roncalli; G Colloredo; G Leandro; F Oliveri; M Derenzini
Journal:  Mol Pathol       Date:  1998-04

9.  Morphometric study of hepatocytes containing hepatitis B surface antigen.

Authors:  M L Chen; M A Gerber; S N Thung; J C Thornton; W K Chung
Journal:  Am J Pathol       Date:  1984-02       Impact factor: 4.307

10.  A case report of hepatocellular carcinoma within adenomatous hyperplasia: is adenomatous hyperplasia a precancerous lesion or not?

Authors:  A Itoh; H Taniguchi; K Sawai; T Takahashi; K Kawamoto; T Deguchi; K Kagawa
Journal:  Gastroenterol Jpn       Date:  1991-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.